中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
17期
9-12
,共4页
肺腺癌%表皮生长因子受体%肿瘤标记物
肺腺癌%錶皮生長因子受體%腫瘤標記物
폐선암%표피생장인자수체%종류표기물
Lung adenocarcinoma%Epidemeral growth factor receptor%Tumor markers
目的 观察肺腺癌表皮生长因子受体(EGFR)基因突变和血清多种肿瘤标记物的相关性.方法 通过PCR扩增及DNA测序分析70例肺腺癌EGFR 19、21外显子基因突变,同期蛋白芯片-化学发光法检测血清中肿瘤标记物[癌胚抗原(CEA)、糖类抗原(CA125)、CA199、C242和CA153]水平,统计分析所得结果.结果 EGFR基因突变组的血清CEA、CA199和CA242水平较野生型组高;血清CEA和CA242水平高者EGFR基因突变率高,CEA、CA242及两者联合检测的曲线下面积(AUC)分别为0.724、0.769和0.738,预测EGFR基因突变的敏感性分别为70.4%、37.0%和77.8%.结论 血清CEA和CA242水平可作为预测EGFR基因突变指标.
目的 觀察肺腺癌錶皮生長因子受體(EGFR)基因突變和血清多種腫瘤標記物的相關性.方法 通過PCR擴增及DNA測序分析70例肺腺癌EGFR 19、21外顯子基因突變,同期蛋白芯片-化學髮光法檢測血清中腫瘤標記物[癌胚抗原(CEA)、糖類抗原(CA125)、CA199、C242和CA153]水平,統計分析所得結果.結果 EGFR基因突變組的血清CEA、CA199和CA242水平較野生型組高;血清CEA和CA242水平高者EGFR基因突變率高,CEA、CA242及兩者聯閤檢測的麯線下麵積(AUC)分彆為0.724、0.769和0.738,預測EGFR基因突變的敏感性分彆為70.4%、37.0%和77.8%.結論 血清CEA和CA242水平可作為預測EGFR基因突變指標.
목적 관찰폐선암표피생장인자수체(EGFR)기인돌변화혈청다충종류표기물적상관성.방법 통과PCR확증급DNA측서분석70례폐선암EGFR 19、21외현자기인돌변,동기단백심편-화학발광법검측혈청중종류표기물[암배항원(CEA)、당류항원(CA125)、CA199、C242화CA153]수평,통계분석소득결과.결과 EGFR기인돌변조적혈청CEA、CA199화CA242수평교야생형조고;혈청CEA화CA242수평고자EGFR기인돌변솔고,CEA、CA242급량자연합검측적곡선하면적(AUC)분별위0.724、0.769화0.738,예측EGFR기인돌변적민감성분별위70.4%、37.0%화77.8%.결론 혈청CEA화CA242수평가작위예측EGFR기인돌변지표.
Objective To analyze the correlation between the epidemeral growth factor receptor (EGFR) gene mutations and the level of tumor markers in lung adenocarcinoma.Methods EGFR gene was amplified by PCR and sequenced to detect EGFR mutation in 70 lung adenocarcinoma patients,and tumor marks were detected with protein chip-chemiluminescence way,statistical analysis was carried out.Results The serum levels of CA199,CEA and CA242 in EGFR mutation group were higher than those in the wild,high serological CEA and CA242 level had higher rate in the EGFR gene mutation.The areas of CEA,CA242 and the both under the curve were 0.724,0.769 and 0.738,respectively ; the sensitivity to predict EGFR gene mutation were 70.4%,37% and 77.8%,respectively.Conclusions The level of serological CEA and CA242 can be used as indicators to forecast EGFR gene mutations.